Pharmacologic degradation of WDR5 suppresses oncogenic activities of SS18::SSX and provides a therapeutic of synovial sarcoma
Sign Up to like & getrecommendations! Published in 2025 at "Science Advances"
DOI: 10.1126/sciadv.ads7876
Abstract: Cancer-causing aberrations recurrently target the chromatic-regulatory factors, leading to epigenetic dysregulation. Almost all patients with synovial sarcoma (SS) carry a characteristic gene fusion, SS18::SSX, which produces a disease-specific oncoprotein that is incorporated into the switch/sucrose… read more here.
Keywords: pharmacologic degradation; ss18 ssx; wdr5; synovial sarcoma ... See more keywords